Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$143.49 USD

143.49
736,466

+3.55 (2.54%)

Updated Oct 9, 2024 04:00 PM ET

After-Market: $143.53 +0.04 (0.03%) 6:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Integra Lifesciences Picked for Healogics iSupply Program

Integra Lifesciences' (IART) selection as a key provider for cellular-based tissue products within Healogics' new iSupply program to boost the top line.

    Varian Up on Tie-Up With Kenya's Mediheal Group of Hospitals

    Varian's (VAR) advanced cancer care solution prospects bright in the global market.

      Here's Why You Should Invest in Surmodics (SRDX) Stock Now

      Continuous focus on R&D and a raised guidance for fiscal 2018 make Surmodics (SRDX) a lucrative pick for investors.

        IDEXX Gains Ground on Solid CAG Business Amid Forex Woes

        IDEXX (IDXX) continues to see strong organic growth, driven by solid sales at the CAG business. However, unfavorable currency movement remains a concern.

          Here's Why You Should Hold On to Quest Diagnostics (DGX) Now

          Tough competitive landscape and reimbursement issues are major deterrents to Quest Diagnostics' (DGX) top line in the near term. The company's focus on promising areas to drive growth is a positive.

            Boston Scientific to Boost MedSurg Unit Via Augmenix Buyout

            Boston Scientific (BSX) continues to adopt organic as well as inorganic means to boost top line.

              Penumbra Launches Reperfusion Catheters, Boosts Neuro Unit

              Penumbra (PEN) adopts initiatives to boost the highest revenue generating Neuro business.

                Genomic Health Prostate Cancer Business Solid, Cost Woes Stay

                Within the prostate cancer space, Genomic Health (GHDX) is seeing increasing private coverage for the Oncotype DX GPS test. Costs and operating expenses continue to rise.

                  Here's Why You Should Invest in athenahealth (ATHN) Now

                  Focus on cloud-based services and a lifted guidance for 2018 make athenahealth (ATHN) an attractive pick.

                    Varian's (VAR) ProBeam System Gets Picked by Delray Medical

                    Varian Medical's (VAR) coveted ProBeam platform sees a slew of developments; market prospects solid.

                      Here's Why You Should Hold on to Abiomed (ABMD) for Now

                      Abiomed's (ABMD) margin continues to remain pressed; an upbeat view for fiscal 2019 encourages.

                        Amedisys Ties Up With Medalogix to Boost Home Health Unit

                        Amedisys (AMED) pursues deals to boost Home Health business.

                          Here's Why You Should Invest in Veeva (VEEV) Stock Right Now

                          Strong fundamentals and a solid Q2 aid Veeva (VEEV).

                            Illumina MiSeq Dx Okayed in China, NGS Platform Gets a Boost

                            Illumina's (ILMN) receipt of CNDA approval for MiSeq Dx Sequencing System is expected to expand customer base and boost the top line.

                              Here's Why You Should Invest in Phibro (PAHC) Right Now

                              Phibro (PAHC) sees improvement across all segments. The Animal Health business has been a key contributor.

                                Here's Why You Should Buy Inogen (INGN) Stock Right Now

                                Inogen (INGN) gains from strong Q2 results and bright global prospects.

                                  Here's Why You Should Invest in Genomic Health (GHDX) Now

                                  Genomic Health (GHDX) gains ground on growing adoption of prostate cancer test and solid international scenario.

                                    Ecolab's Nalco Pairs With XOS to Boost Global Energy Unit

                                    Ecolab's (ECL) Nalco Champion's 3D CRUDEFLEX will integrate XOS' Clora Online; market prospects bright.

                                      New Buyouts Aid Boston Scientific Amid Dull Pacemaker Sales

                                      Boston Scientific (BSX) continues to adopt organic as well as inorganic routes for success. However, sluggish global pacemaker sales continue to disappoint.

                                        Wright Medical Buys Cartiva to Boost Lower Extremities Unit

                                        Wright Medical's (WMGI) addition of Synthetic Cartilage Implant is likely to drive revenues in 2019; raised guidance for 2018 encourages.

                                          STERIS (STE) Strategic Growth Strong, Competition a Woe

                                          STERIS' (STE) beneficial underlying market trends along with new product and service offerings are impressive. Meanwhile, the company worries over facing a severe competition.

                                            Bruker to Expand Molecular Diagnostics Arm With Hain Buyout

                                            Hain's molecular diagnostics solutions of bacterial and viral infections are expected to compliment Bruker's (BRKR) MALDI Biotyper and IR Biotyper microbiology platforms.

                                              Omnicell Patient Engagement Unit to Aid Medication Adherence

                                              Omnicell's (OMCL) revamped Patient Engagement platform likely to aid core Medication Adherence Unit; market looks promising.

                                                Sweta Jaiswal headshot

                                                Tap the Sleep Apnea Devices Market Boom With These 3 Stocks

                                                Consider these three stocks in the sleep apnea devices market for grand returns.

                                                  Hill-Rom (HRC) Touches 52-Week High: What's Driving It?

                                                  Hill-Rom (HRC) rides high on impressive Q3 results along with increased focus on product innovation through research and development.